Results 41 to 50 of about 76,191 (305)
Non-infectious pulmonary complications of hematopoietic stem cell transplantation [PDF]
, 2014 Noninfectious pulmonary complications of hematopoietic stem cell transplant are currently more prevalent than infectious complications. Unfortunately, the pathophysiology basis is not completely understood.
Baloglu, Orkun +2 more
core +1 more source
Dexamethasone palmitate ameliorates macrophages-rich graft-versus-host disease by inhibiting macrophage functions. [PDF]
PLoS ONE, 2014 Macrophage infiltration of skin GVHD lesions correlates directly with disease severity, but the mechanisms underlying this relationship remain unclear and GVHD with many macrophages is a therapeutic challenge.
Satoshi Nishiwaki +18 more
doaj +1 more source
TWEAKing for a fight with GVHD [PDF]
Blood, 2015 In this issue of Blood, Chopra et al provide convincing evidence that tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) ligand acting through its receptor, fibroblast growth factor-inducible 14 (Fn14), is crucial to the intestinal apoptosis seen in graft-versus-host disease (GVHD) and associated mortality.
openaire +3 more sources
A multicentre UK study of GVHD following DLI: Rates of GVHD are high but mortality from GVHD is infrequent [PDF]
Bone Marrow Transplantation, 2014 DLIs are frequently used following haematopoietic SCT (HSCT) in patients with risk of relapse but data on GVHD following DLI are scarce. We report on 68 patients who received DLI following HSCT. Most patients developed GVHD following DLI (71%), which was acute in 22 patients (32%) almost half of whom had grade III-IV acute GVHD (aGVHD). Thirty patients
Ghulam J. Mufti +12 more
openaire +3 more sources
Alteration in the Skin Microbiome in Cutaneous Graft Versus Host Disease
Acta Dermato-Venereologica, 2021 Graft versus host disease (GVHD) is a common complication of haematopoietic stem cell transplantation. This study examined the cutaneous microbiome in relation to the pathogenesis of cutaneous GVHD.
Ying Gu +4 more
doaj +1 more source
Prevention and treatment of acute GvHD [PDF]
Bone Marrow Transplantation, 2008 GvHD remains a source of significant morbidity and mortality in the setting of allogeneic haematopoietic SCT. Improving outcomes in stem cell transplant recipients requires additional therapeutic modalities for GvHD, especially for patients who fail to respond to initial therapy with steroids.
MESSINA, CHIARA +5 more
openaire +4 more sources
Turkish Journal of Hematology, 2013 Objective: Graft-versus-host disease (GVHD) is a major obstacle to successful allogeneic bone marrow transplantation (allo-BMT). While multipotent mesenchymal stromal cells (MSCs) demonstrate alloresponse in vitro and in vivo, they also have clinical ...
Oral Nevruz +9 more
doaj +1 more source
New strategies in GVHD prophylaxis [PDF]
Bone Marrow Transplantation, 2000 Despite immunosuppressive therapy using cyclosporine (CsA) and prednisolone and methotrexate (MTX), the incidence for aGVHD grade II to IV after transplantation from HLA matched unrelated donors (MUD) is 78%, the incidence for grade III and IV 36%. Since GVHD contributes to morbidity and mortality after MUD-BMT, a more effective prophylactic regimen is
Kiehl, M. G. +4 more
openaire +4 more sources
Immunomagnetic t-lymphocyte depletion (ITLD) of rat bone marrow using OX-19 monoclonal antibody [PDF]
, 1989 Graft versus host disease (GVHD) may be abrogated and host survival prolonged by in vitro depletion of T lymphocytes from bone marrow (BM) prior to allotransplantation. Using a mouse anti-rat pan T-lymphocyte monoclonal antibody (0×19) bound to monosized,
A. Pascualone +30 more
core +1 more source
Pharmaceuticals, 2022 Haploidentical hematopoietic stem cell transplantation using post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis has emerged as a valid alternative transplant strategy for patients lacking a suitable HLA-matched ...
Kang-Hsi Wu +3 more
doaj +1 more source